Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Silexion Therapeutics Corporation | SLXNW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0478 | 08:30:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0478 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.0478 | USD |
Silexion Therapeutics Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 76.63k | - | - | - | 0.16 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Silexion Therapeutics
| Date | Time | Source | Heading |
|---|---|---|---|
| 1/17/2025 | 05:56 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/17/2025 | 05:44 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 1/15/2025 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 1/15/2025 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/15/2025 | 05:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/14/2025 | 16:02 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
| 1/14/2025 | 05:19 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
| 1/14/2025 | 05:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/18/2024 | 05:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
| 12/17/2024 | 06:08 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/10/2024 | 08:42 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 12/10/2024 | 08:41 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SLXNW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. |
NASDAQ:SLXNW -
What is the current Silexion Therapeutics Corporation share price?
The current share price of Silexion Therapeutics Corporation is US$ 0.0478
What is the 1 year trading range for Silexion Therapeutics Corporation share price?
Silexion Therapeutics Corporation has traded in the range of US$ 0.00 to US$ 0.00 during the past year
